{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:10:53Z","timestamp":1789737053995,"version":"4.0.1"},"reference-count":9,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1979,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1111\/j.1365-2885.2009.01133.x","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T03:28:28Z","timestamp":1268105308000},"page":"162-171","source":"Crossref","is-referenced-by-count":39,"title":["Pharmacokinetic properties of toceranib phosphate (Palladia\u2122, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors"],"prefix":"10.1111","volume":"33","author":[{"given":"M. F.","family":"YANCEY","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"MERRITT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"LESMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. F.","family":"BOUCHER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"MICHELS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"10.1111\/j.1365-2885.2009.01133.x-BIB1","unstructured":"FDA Guidance for Industry. Bioanalytical Method Validation. http:\/\/www.fda.gov\/cder\/guidance\/4252fnl.pdf (2001). Accessed 21Jan2009."},{"key":"10.1111\/j.1365-2885.2009.01133.x-BIB2","volume-title":"Drug Interactions: Cytochrome P450 Drug Interaction Table","author":"Flockhart","year":"2007"},{"key":"10.1111\/j.1365-2885.2009.01133.x-BIB3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1182\/blood-2001-12-0350","article-title":"Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors","volume":"100","author":"Liao","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1365-2885.2009.01133.x-BIB4","first-page":"2755","article-title":"Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies","volume":"9","author":"London","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/j.1365-2885.2009.01133.x-BIB5","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","article-title":"Multicenter, placebo-controlled, double-blind randomized study of oral Toceranib Phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either Local or Distant) mast cell tumor following surgical excision","volume":"15","author":"London","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/j.1365-2885.2009.01133.x-BIB6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0169-409X(02)00070-4","article-title":"Applying the biopharmaceutics classification system to veterinary pharmaceutical products Part I: biopharmaceutics and formulation considerations","volume":"54","author":"Martinez","year":"2002","journal-title":"Adv Drug Deliver Rev"},{"key":"10.1111\/j.1365-2885.2009.01133.x-BIB7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/(SICI)1099-081X(199610)17:7<635::AID-BDD981>3.0.CO;2-4","article-title":"Short Communication: \u2018Pavlovian\u2019 food effect on the enterohepatic recirculation of piroxicam","volume":"17","author":"Polli","year":"1996","journal-title":"Biopharmaceutics and Drug Disposition"},{"key":"10.1111\/j.1365-2885.2009.01133.x-BIB8","first-page":"5729","article-title":"Proof of Target for SU11654: inhibition of KIT phosphorylation in Canine mast cell tumors","volume":"9","author":"Pryer","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/j.1365-2885.2009.01133.x-BIB9","article-title":"Distribution, metabolism, and excretion of Toceranib phosphate (Palladia\u2122, SU11654), a novel tyrosine kinase inhibitor, in dogs","author":"Yancey","year":"2009","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2885.2009.01133.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2885.2009.01133.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T08:50:27Z","timestamp":1625561427000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2885.2009.01133.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2885.2009.01133.x","relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}